-
公开(公告)号：US20150297693A1
公开(公告)日：2015-10-22
申请号：US14754835
申请日：2015-06-30
Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventor： Johannes HERKEL , Irun R. COHEN , Varda ROTTER , Ansgar W. LOHSE , Neta EREZ , Avishai MIMRAN , Na'aman KAM
IPC: A61K39/00
CPC classification number: A61K39/0008 , A61K38/00 , A61K39/0005 , C07K7/06 , C07K7/08 , C07K14/435
Abstract: The present invention relates to peptides capable of inhibiting cellular and immune stress responses in a eukaryotic cell. The invention provides compositions and methods for the treatment of human degenerative diseases and inflammation, utilizing these peptides.
Abstract translation: 本发明涉及能够抑制真核细胞中的细胞和免疫应答反应的肽。 本发明提供了利用这些肽治疗人退行性疾病和炎症的组合物和方法。
-
公开(公告)号：US20210041455A1
公开(公告)日：2021-02-11
申请号：US17081013
申请日：2020-10-27
Inventor： Eran OVADIA , Irun R. COHEN , Johannes HERKEL , Raanan MARGALIT , Meirav PEVSNER-FISCHER
IPC: G01N33/68 , A61K38/18 , G01N33/543 , A61K38/30 , C07K7/06 , A61K31/343 , A61K45/06 , A61K38/08
Abstract: The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.
-
3.发明申请公开(公告)号：US20190204340A1
公开(公告)日：2019-07-04
申请号：US16352879
申请日：2019-03-14
Inventor： Eran OVADIA , Irun R. COHEN , Johannes HERKEL , Raanan MARGALIT , Meirav PEVSNER-FISCHER
IPC: G01N33/68 , G01N33/543 , A61K31/343 , A61K45/06 , C07K7/06 , A61K38/30 , A61K38/18 , A61K38/08
CPC classification number: G01N33/6854 , A61K31/343 , A61K38/08 , A61K38/1808 , A61K38/1825 , A61K38/1833 , A61K38/1841 , A61K38/185 , A61K38/1866 , A61K38/1891 , A61K38/30 , A61K45/06 , C07K7/06 , G01N33/54306 , G01N33/6896 , G01N2800/28 , G01N2800/52 , A61K2300/00
Abstract: The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.
-
4.发明申请USE OF AKT PHOSPHORYLATION AS A BIOMARKER FOR PROGNOSING NEURODEGENERATIVE DISEASES AND TREATING SAME 审中-公开作为生物标记用于预防神经损伤性疾病和治疗的AKT磷酸化的使用公开(公告)号：US20160033529A1
公开(公告)日：2016-02-04
申请号：US14883685
申请日：2015-10-15
Inventor： Eran OVADIA , Irun R. COHEN , Johannes HERKEL , Raanan MARGALIT , Meirav PEVSNER-FISCHER
IPC: G01N33/68
CPC classification number: G01N33/6854 , A61K31/343 , A61K38/08 , A61K38/1808 , A61K38/1825 , A61K38/1833 , A61K38/1841 , A61K38/185 , A61K38/1866 , A61K38/1891 , A61K38/30 , A61K45/06 , C07K7/06 , G01N33/54306 , G01N33/6896 , G01N2800/28 , G01N2800/52 , A61K2300/00
Abstract: The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.
Abstract translation: 本发明涉及包含选自SEQ ID NO：1，SEQ ID NO：2，其类似物和衍生物的氨基酸序列的肽用于治疗神经变性疾病如肌萎缩性侧索硬化（ ALS）。 本发明还提供了评估对本发明的肽的治疗反应性的方法。 此外，本发明涉及使用Akt和磷酸化Akt作为生物标志物的ALS进展的预后。
-
-
-
Search Results
4
records
(took 0.018 seconds)
